Valneva SE (VALN) Net Income (2021 - 2026)
Valneva SE (VALN) posted Net Income of -$38.5 million for Q1 2026, up 33.98% sequentially from -$58.3 million in Q4 2025, and down 240.92% YoY from $27.3 million in Q1 2025.
Valneva SE (VALN) Net Income (2021 - 2026) Analysis & Trends
Valneva SE has reported Net Income for 6 years, with the latest figure at -$38.5 million in Q1 2026.
- Quarterly Net Income fell 240.92% year-over-year to -$38.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$162.5 million (down 83.46% YoY) and the FY2025 annual result came in at -$134.1 million, down 849.77% from the prior year.
- Net Income climbed to -$38.5 million in Q1 2026 per VALN's latest filing, from -$58.3 million in the prior quarter.
- Over five years, Net Income peaked at $272.8 million in Q3 2022 and troughed at -$247.3 million in Q4 2022.
- A 5-year average of -$27.3 million and a median of -$38.5 million in 2026 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income soared 228.93% in 2024, then slumped 768.27% in 2025.
- Over 5 years, Net Income stood at -$247.3 million in 2022, then jumped by 84.31% to -$38.8 million in 2023, then slipped by 14.82% to -$44.5 million in 2024, then sank by 30.86% to -$58.3 million in 2025, then jumped by 33.98% to -$38.5 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$38.5 million, -$58.3 million, and -$52.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -36.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.30 Mn |
| Mar 31, 2026 | -38.49 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -52.79 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Mar 31, 2025 | -11.29 Mn |
| Dec 31, 2024 | -44.55 Mn |
| Sep 30, 2024 | -6.08 Mn |
| Jun 30, 2024 | -26.64 Mn |
| Mar 31, 2024 | 64.00 Mn |
| Dec 31, 2023 | -38.80 Mn |
| Sep 30, 2023 | -40.17 Mn |
| Jun 30, 2023 | -57.90 Mn |
| Mar 31, 2023 | 19.46 Mn |
| Dec 31, 2022 | -247.26 Mn |
| Sep 30, 2022 | 272.81 Mn |
| Jun 30, 2022 | -155.21 Mn |
| Mar 31, 2022 | -29.23 Mn |
| Dec 31, 2021 | -365.34 Mn |
| Sep 30, 2021 | 188.14 Mn |